Is India right in recommending HCQ despite the uncertainties around it?

The World Health Organisation (WHO) has resumed the trials on hydroxychloroquine (HCQ), the drug that became famous after the US President spoke about its efficacy. HCQ was dropped from the solidarity trial that WHO was conducting as a part of a global effort in May.   This was done after peer reviewed medical journal The Lancet said that HCQ can lead to increased mortality rates and came with risks of adverse effects like cardiac arrhythmia. On Wednesday, The Lancet red-flagged the study. It has issued a statement of concern now after more than 100 scientists across the world flagg.....

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel
Key stories on business-standard.com are available to premium subscribers only.

Already a premium subscriber?

Subscribe to get an across device (Website, Mobile Web, Iphone, Ipad, and Android Phone applications) access to Premium content, Breaking News alerts, Industry Newsletters, Stock and Corporate news alerts, access to Archives and a lot more.